Publications by authors named "Julia H Keating"
Article Synopsis
- In a phase 1b study, the BCL2 inhibitor venetoclax was tested alongside a reduced chemotherapy regimen in patients with acute lymphoblastic leukemia (ALL) to determine the optimal dose while minimizing toxicity.
- The study included 19 patients, with 90.9% of those newly diagnosed achieving complete remission and showing no deaths or serious toxicities within 60 days.
- Results indicated that the combination therapy is well-tolerated and effective, especially in newly diagnosed patients, with a median disease-free survival of 54.6 months.
Article Synopsis
- Dasatinib is a treatment for Philadelphia chromosome-positive (Ph+) acute leukemia, but some patients develop resistance, leading to the exploration of combining it with asciminib, an allosteric inhibitor to enhance efficacy.
- In a phase 1 study involving 24 adults, researchers aimed to determine the maximum tolerated dose of asciminib when used alongside dasatinib and prednisone for Ph+ acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) in lymphoid blast crisis.
- Results showed that the combination led to high rates of complete hematologic and cytogenetic remission, with the recommended dose of asciminib being 80 mg daily, while also demonstrating safety and minimal severe side effects.
